Literature DB >> 17341246

Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults.

Joseph V Agostini1, Mary E Tinetti, Ling Han, Gail McAvay, Joanne M Foody, John Concato.   

Abstract

OBJECTIVES: To determine the relationship between hydroxymethyl glutaryl coenzyme A reductase inhibitor (statin) use and proximal muscle strength, cognition, and depression in older adults.
DESIGN: Observational cohort study.
SETTING: Outpatient primary care clinics. PARTICIPANTS: Seven hundred fifty-six community-dwelling veterans aged 65 and older. MEASUREMENTS: Timed chair stands (a measure of proximal muscle strength), Trail Making Test Part B (a measure of cognition), and the Center for Epidemiologic Studies Depression Scale score were measured at baseline and 1-year follow-up. Participants were assessed for statin prescriptions (and indications for or contraindications to their use), concomitant medication use, comorbidities, and other potential confounders.
RESULTS: Statin users (n=315) took a mean 6.6 medications, versus 4.6 for nonusers (n=441), and had a median duration of statin use of 727 days. Statin users were more likely to be white and had (as expected) more cardiac, cerebrovascular, and peripheral vascular disease. Based on multivariable models adjusting for pertinent covariates, statin users performed modestly better than nonusers for timed chair stands (-0.5 seconds; P=.04), Trail Making Test Part B (-7.7 seconds; P=.08), and depression scores (-0.2 points; P=.49) at follow-up. Of potentially high-risk participants (based on age, comorbidity, and number of medications), statin users also showed similar 1-year changes as nonusers, although worsened depression scores were found in those with greater comorbidity (+0.88 points; P=.10).
CONCLUSION: Older, community-dwelling male participants taking maintenance statin therapy had similar outcomes to those of nonusers in tests of muscle strength, cognition, and depression, but further examination of benefits and harms in different subgroups is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341246     DOI: 10.1111/j.1532-5415.2007.01071.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  33 in total

1.  Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

2.  Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis.

Authors:  Cynthia M Carlsson; David M Nondahl; Barbara E K Klein; Patrick E McBride; Mark A Sager; Carla R Schubert; Ronald Klein; Karen J Cruickshanks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

Review 3.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

4.  Association between statin use at admission to inpatient rehabilitation and functional status at discharge among older patients.

Authors:  Alessandro Morandi; Timothy D Girard; Ayumi Shintani; Renato Turco; Fabio Guerini; Tiziana Torpilliesi; Simona Gentile; Marco Trabucchi; Giuseppe Bellelli
Journal:  Rejuvenation Res       Date:  2014-12       Impact factor: 4.663

5.  A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.

Authors:  Paul D Thompson; Beth A Parker; Priscilla M Clarkson; Linda S Pescatello; C Michael White; Adam S Grimaldi; Benjamin D Levine; Ronald G Haller; Eric P Hoffman
Journal:  Prev Cardiol       Date:  2010

Review 6.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

7.  Lipid-lowering drugs associated with slower motor decline in the elderly adults.

Authors:  Julien Dumurgier; Archana Singh-Manoux; Béatrice Tavernier; Christophe Tzourio; Alexis Elbaz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-10-04       Impact factor: 6.053

Review 8.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

9.  Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study.

Authors:  T A Ashfield; H E Syddall; H J Martin; E M Dennison; C Cooper; A Aihie Sayer
Journal:  Age Ageing       Date:  2009-12-17       Impact factor: 10.668

10.  Brief depression screening with the PHQ-2 associated with prognosis following percutaneous coronary intervention with paclitaxel-eluting stenting.

Authors:  Susanne S Pedersen; Johan Denollet; Peter de Jonge; Cihan Simsek; Patrick W Serruys; Ron T van Domburg
Journal:  J Gen Intern Med       Date:  2009-07-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.